pd1/pdl1

Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling.

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Avelumab is a humanized anti-PD-L1 monoclonal antibody that binds to PD-L1 with high specificity (Kd = 0.1 nM) and exhibits potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab exerts a dual mechanism of action, combining direct antitumor activity with ADCC. Avelumab is used in research on cancers such as Merkel cell carcinoma.

Nivolumab is a monoclonal antibody and is a humanized PD-1 antibody. Nivolumab has anti-tumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, etc.

Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC₅₀ values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

BMS-202 (PD1-PDL1 inhibitor 2) is a non-peptide PD-1/PD-L complex inhibitor with an IC₅₀ of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 with high affinity and blocks human PD-1/PD-L interactions, exhibiting antitumor activity.

BMS-1 (PD-1/PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1/PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1].

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).

PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.

PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction, with an IC₅₀ of 92.3 nM.

ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.

BMS-1166-n-piperidine-co-n-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. It contains the target protein PD-1/PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1/PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.

ARB-272572 hydrochloride is a small molecule PD-L1 inhibitor with an IC₅₀ value of 400 pM for PD-1/PD-L1 HTRF.ARB-272572 hydrochloride inhibits PD-1/PD-L1 cell signaling by inducing homologous interactions with PD-L1 proteins.

PD-1/PD-L1-IN-9, with an IC₅₀ of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.

Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.

Sulindac (Sulindac sulfoxide) is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.

Acesulfame potassium is a non-nutritive sweetener.

Manelimab is a humanized monoclonal antibody targeting Programmed death-ligand 1(PD-L1). By blocking the interaction between PD-L1 and its receptor PD-1, it can relieve the immunosuppression of T cells, thus enhancing the anti-tumor immune response. Manelimab is mainly used to explore the mechanism of tumor immunotherapy.

Anti-Human/Mouse/Monkey PD-1 Antibody (2E5) is a monoclonal inhibitory antibody targeting PD-1. PD-1 is a cell membrane receptor mainly expressed on the surface of T cells and pre-B cells. Binding of PD-1 to its ligands PD-L1 and PD-L2 reduces the body’s immune response by inhibiting T cell activation. Therefore, PD-1 serves as a key immune checkpoint and an important target for the development of targeted antibody drugs for various malignant tumors.